Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?-Reference-Cited by-同舟云学术

Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?

Published:2009-05 Issue:5 Volume:26 Page:469-487
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Therapy

Author:

Fabbri Gianna,Maggioni Aldo Pietro

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://www.springerlink.com/index/pdf/10.1007/s12325-009-0025-6

Reference100 articles.

1. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291:2616–2622.

2. Cardiovascular diseases. Fact sheet no. 317. February 2007. World Health Organization web site. Available at: www.who.int. Accessed April 2009.

3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239.

4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.

5. Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. N Engl J Med. 1998;339:1349–1357.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contradictions in traditional ideas about atherosclerosis and the efficacy of lipid-lowering therapy. Promising directions;Сибирский научный медицинский журнал;2024-08-28

2. Analysis of the relationship between the level of high-sensitive C-reactive protein and the risk factors of cardiovascular diseases in young and middle-aged persons;Medical alphabet;2021-10-02

3. Physicochemical characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated solid lipid nanoparticles;International Journal of Pharmaceutics;2020-03

4. Rosuvastatin inhibits high glucose-stimulated upregulation of VCAM-1 via the MAPK-signalling pathway in endothelial cells;Acta Cardiologica;2017-09-08

5. Improved intestinal lymphatic drug targeting via phospholipid complex-loaded nanolipospheres of rosuvastatin calcium;RSC Advances;2016